United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2014_register executive 2014-10-07 article Notices D09002ee1c7f89fe7 D09002ee1c7f8a065 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Patent Application No. 60/844,027 entitled, "Azonafide derived tumor and cancer targeting compounds," filed September 12, 2006 [HHS Ref. No. E- 160-2006/0-US-01], PCT Application No. PCT/US2007/078233 entitled, "Azonafide derived tumor and cancer targeting compounds," filed September 12, 2007 [HHS Ref. No. E-160-2006/0-PCT-02], European Patent Application No. 7842310.0 entitled, "Azonafide derived tumor and cancer targeting compounds," filed September 12, 2007 [HHS Ref. No. E- 160-2006/0-EP-03], and U.S. Patent Application No. 12/441,029 entitled, "Azonafide derived tumor and cancer targeting compounds," filed March 12, 2009 now US Patent No. 8,008,316 issued August 30, 2011 [HHS Ref. No. E-160-2006/0-US-04], and all related continuing and foreign patents/patent applications for the technology family, to Oncolinx, Inc. The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to the development and use of the licensed patent rights as a component of an antibody-drug conjugate for the treatment of human cancers. Upon expiration or termination of the exclusive evaluation option license, Oncolinx will have the right to execute an exclusive patent commercialization license which will supersede and replace the exclusive evaluation option license with no broader territory than granted in the exclusive evaluation option license and the field of use will be commensurate with the commercial development plan at the time of conversion. 79 FR 54987 https://www.govinfo.gov/app/details/FR-2014-09-15/2014-21855 2014-21855 fr15se14-63 4140-01-P https://www.govinfo.gov/app/details/FR-2014-09-15/2014-21855 https://www.govinfo.gov/content/pkg/FR-2014-09-15/html/2014-21855.htm https://www.govinfo.gov/content/pkg/FR-2014-09-15/pdf/2014-21855.pdf 1 p. 54987 54987 79 FR 54987 Prospective Grant of Exclusive Evaluation License: Development of Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the Treatment of Human Cancers; Federal Register Vol. 79, Issue NOTICE 2014-21855 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2014-09-30 4140-01-P 2014-21855 Notice.

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Patent Application No. 60/844,027 entitled, "Azonafide derived tumor and cancer targeting compounds," filed September 12, 2006 [HHS Ref. No. E- 160-2006/0-US-01], PCT Application No. PCT/US2007/078233 entitled, "Azonafide derived tumor and cancer targeting compounds," filed September 12, 2007 [HHS Ref. No. E-160-2006/0-PCT-02], European Patent Application No. 7842310.0 entitled, "Azonafide derived tumor and cancer targeting compounds," filed September 12, 2007 [HHS Ref. No. E- 160-2006/0-EP-03], and U.S. Patent Application No. 12/441,029 entitled, "Azonafide derived tumor and cancer targeting compounds," filed March 12, 2009 now US Patent No. 8,008,316 issued August 30, 2011 [HHS Ref. No. E-160-2006/0-US-04], and all related continuing and foreign patents/patent applications for the technology family, to Oncolinx, Inc. The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to the development and use of the licensed patent rights as a component of an antibody-drug conjugate for the treatment of human cancers. Upon expiration or termination of the exclusive evaluation option license, Oncolinx will have the right to execute an exclusive patent commercialization license which will supersede and replace the exclusive evaluation option license with no broader territory than granted in the exclusive evaluation option license and the field of use will be commensurate with the commercial development plan at the time of conversion.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 30, 2014 will be considered. Exclusive Licenses: Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the Treatment of Human Cancers , wongje@od.nih.gov Vol. 79, no. 178 Office of the Federal Register, National Archives and Records Administration 2014-09-15 continuing daily deposited born digital 474 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2014-09-15 P0b002ee189db0129 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr15se14 https://www.govinfo.gov/app/details/FR-2014-09-15 https://www.govinfo.gov/content/pkg/FR-2014-09-15/pdf/FR-2014-09-15.pdf https://www.govinfo.gov/content/pkg/FR-2014-09-15/xml/FR-2014-09-15.xml fdlp 54887 55350 DGPO 2014-10-07 2024-06-02 FR-2014-09-15 machine generated eng FR FR-2014-09-15 79 178